Back to results
US 2025/0270618 A1Published application
Methods for diagnosis and treatment of alzheimer's disease
AssigneeChildren's Medical Center Corporation
InventorsHanno STEEN, Judith STEEN, Patrick W. VAN ZALM
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for diagnosing and treating Alzheimer's disease in a subject comprising determining the expression level of three, four or five members of a panel of proteins in a biological sample obtained from the subject.
Claims27
A method for treating Alzheimer's disease in a subject, the method comprising:
- (i) receiving results of a protein assay relating to the expression of a panel of proteins comprising pyruvate kinase (PKM), fructose bisphosphate aldolase A (ALDOA), and lactate dehydrogenase B chain (LDHB) in a biological sample obtained from a subject,
- (ii) determining that the expression of at least one of the members of the panel of proteins is increased in the biological sample compared to the expression of the at least one member in a reference sample, and
- (iii) administering a treatment for Alzheimer's disease to the subject, thereby treating Alzheimer's disease in the subject.
(canceled)
A method for treating Alzheimer's disease in a subject, the method comprising:
- (i) receiving results of a protein assay relating to the expression of each member of a panel of proteins in a biological sample obtained from a subject, wherein the panel of proteins comprises pyruvate kinase (PKM), fructose bisphosphate aldolase A (ALDOA), lactate dehydrogenase B chain (LDHB), and 14-3-3 protein zeta/delta (YWHAZ),
- (ii) determining that expression of at least one of the members of the panel of proteins is increased in the biological sample as compared to the expression level of the at least one member in a reference sample, and
- (iii) administering a treatment for Alzheimer's disease to the subject, thereby treating Alzheimer's disease in the subject.
11-18. (canceled)
A method for treating Alzheimer's disease in a subject, the method comprising:
- (i) receiving results of a protein assay relating to the expression of each member of a panel of proteins in a biological sample obtained from a subject, wherein the panel of proteins comprises pyruvate kinase (PKM), fructose bisphosphate aldolase A (ALDOA), lactate dehydrogenase B chain (LDHB), and apolipoprotein E isoform 4 (apoE4),
- (ii) determining that the expression of at least one of the members of the panel of proteins is increased in the biological sample as compared to the expression of the at least one member in a reference sample, and
- (iii) administering a treatment for Alzheimer's disease to the subject, thereby treating Alzheimer's disease in the subject.
20-26. (canceled)
A method for treating Alzheimer's disease in a subject, the method comprising:
- (i) receiving results of a protein assay relating to the expression of each member of a panel of proteins in a biological sample obtained from a subject, wherein the panel of proteins comprises pyruvate kinase (PKM), fructose bisphosphate aldolase A (ALDOA), lactate dehydrogenase B chain (LDHB), 14-3-3 protein zeta/delta (YWHAZ) and apolipoprotein E isoform 4 (apoE4),
- (ii) determining that the expression of at least one of the members of the panel of proteins is increased in the biological sample as compared to the expression of the at least one member in a reference sample, and
- (iii) administering a treatment for Alzheimer's disease to the subject, thereby treating Alzheimer's disease in the subject.
(canceled)
A method for treating Alzheimer's disease in a subject, the method comprising:
- (i) receiving results of a protein assay relating to the expression of each member of a panel of proteins in a biological sample obtained from a subject, wherein the panel of proteins comprises at least two of the members of, or consists essentially of, pyruvate kinase (PKM), fructose bisphosphate aldolase A (ALDOA), lactate dehydrogenase B chain (LDHB), 14-3-3 protein zeta/delta (YWHAZ) and apolipoprotein E isoform 4 (apoE4),
- (ii) determining that the expression of at least one of the members of the panel of proteins is increased in the biological sample as compared to the expression of the at least one member in a reference sample;
- and
- (iii) administering a treatment for Alzheimer's disease to the subject, wherein the treatment reduces or alleviates one or more symptoms of Alzheimer's disease in the subject, thereby treating Alzheimer's disease in the subject.
1 more element
(canceled)
Dependencies are inferred from the claim text.